Ipsen’s partner Inspiration Biopharmaceuticals announces hold of phase III clinical trials evaluating IB1001 for the treatment and prevention of hemophilia B

www.ipsen.com/sites/default/files/communiques-presse/PR_IB1001%20Clinical%20Hold_EN_0.pdf